Similarly, the dual BCL-2/BCL-xL inhibitor pelcitoclax, exploiting a prodrug strategy, has shown promising results in reducing thrombocytopenia while maintaining efficacy against metastatic solid tumors [48]. The gene discussed is BCL2L1; the disease is Thrombocytopenia.